Professor Wim Oyen is full Professor of Diagnostic Imaging and Radiotherapy at Humanitas University in Milan, Italy and nuclear medicine physician at the Department of Radiology and Nuclear Medicine of Rijnstate Hospital, Arnhem, The Netherlands. From 2015-2018, he was full Professor of Nuclear Medicine and Molecular Imaging at The Institute of Cancer Research and Head of the Department of Nuclear Medicine of The Royal Marsden Hospital, London, UK. Before working in the UK, he was a nuclear medicine physician and full Professor of Nuclear Medicine at the Radboud University Medical Centre Nijmegen, The Netherlands, serving as Head of the Department of Nuclear Medicine, Member of the Board of the Medical Staff and Director of the Research Institute for Oncology of RadboudUMC. He is currently actively involved in the European Association of Nuclear Medicine (Board Member, pastCongress Chair and EANM President 2019/2020) and the International Cancer Imaging Society (President 2017/2018). Professor Oyen is a member of several Editorial Boards, including the European Journal of Nuclear Medicine and Molecular Imaging and the Journal of Nuclear Medicine.
Professor Oyen’s main research interests are molecular imaging in oncology and infectious diseases and radionuclide therapy of cancer. He is the (co-)author of more than 650 original science and review articles in international peer-reviewed journals.
- Bashir U, Tree A, Mayer E, Levine D, Parker C, Dearnaley D, Oyen WJG. Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatactomy. European Journal of Nuclear Medicine and Molecular Imaging 2019; 46: 901-907.
- Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O’Sullivan JM, Padhani AR, Schalken J, Scher HI, Tombal B, van Moorselaar JA, van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology 2018; 19: e696-e708.
- Hekman MCH, Rijpkema M, Aarntzen EH, Mulder SF, Langenhuijsen JF, Oosterwijk E, Boerman OC, Oyen WJG, Mulders PFA. PET/CT with 89Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion. European Urology 2018; 74: 257-260.
- Martins CD, Da Pieve C, Smith R, Ciobota DM, Allott L, Harrington KJ, Oyen WJG, SmithG, Kramer-Marek G. HER3-Mediated Resistance to HSP90 Inhibition Detected in Breast Cancer Xenografts by Affibody-based PET Imaging. Clinical Cancer Research 2018; 24: 1853-1865.
- Wong KH, Panek R, Dunlop A, Mcquaid D, Riddell A, Liam C Welsh LC, Murray I, Koh DM, Leach MO, Bhide S, Nutting CM, Oyen WJG, Harrington KJ, Newbold KL. Evaluation of early intra-treatment changes in multimodality functional imaging parameters as predictive biomarkers for response in patients with locally advanced head and neck squamous cell carcinoma undergoing radical chemoradiotherapy. European Journal of Nuclear Medicine and Molecular Imaging 2018; 45: 759-767.